Results 171 to 180 of about 12,173,418 (313)

"On Suggestion" by John Bostock, 1923: A comparison with twenty-first century understandings of the placebo effect. [PDF]

Australas Psychiatry, 2023
Clayton A.
europepmc   +1 more source

Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety Up to 52 Weeks From the Randomized, Double‐Blind, Phase 3 POETYK PsA‐2 Trial

Arthritis &Rheumatology, EarlyView.
Objective To assess the efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with psoriatic arthritis (PsA) who were naive to biologic disease‐modifying antirheumatic drugs or received tumor necrosis factor inhibitors. Methods In the 52‐week, double‐blind, placebo‐controlled, phase 3 Program for Evaluation
Philip J. Mease, Vinod Chandran, April W. Armstrong, Ricardo Blanco, Alexis Ogdie, Evan L. Siegel, Alice B. Gottlieb, Xiaofeng Zeng, Diamant Thaçi, Mitsumasa Kishimoto, Hendrik Schulze‐Koops, Alan Kivitz, Eva Dokoupilová, Akimichi Morita, Eric M. Ruderman, Michael Plewinski, Kejia Wang, Caroline Sardinas, Eleni Vritzali, John Vaile, Atul Deodhar   +20 more
wiley   +1 more source

Beyond the placebo effect: a systematic review and a network meta-analysis of treatment strategies for vulvodynia. [PDF]

BMC Womens Health
Spinillo A, Dominoni M, Tiranini L, Cassani C, Nappi RE, Gardella B.   +5 more
europepmc   +1 more source

Presenting a sham treatment as personalised increases the placebo effect in a randomised controlled trial. [PDF]

Elife, 2023
Sandra DA, Olson JA, Langer EJ, Roy M.
europepmc   +1 more source

Abatacept Reduces CD319+ (SLAMF7) Cytotoxic T Cells and Cytokine Production in Systemic Sclerosis

Arthritis &Rheumatology, EarlyView.
Objective Systemic sclerosis (SSc) is characterized by immune dysregulation and fibrosis. We investigated whether abatacept modulates CD319/SLAMF7‐expressing cytotoxic T cells implicated in diffuse cutaneous SSc. Methods In this ancillary ASSET trial analysis, peripheral blood mononuclear cells from 67 participants were analyzed at baseline and months ...
Mikel Gurrea‐Rubio, Laura A. Cooney, Kohei Maeda, Phillip L. Campbell, Qi Wu, Camila I. Amarista, Alexander Stinson, Ray Ohara, Yang Mao‐Draayer, Michael L. Whitfield, Shiv Pillai, Poulami Dey, Johann E. Gudjonsson, Pei‐Suen Tsou, Dinesh Khanna, David A. Fox   +15 more
wiley   +1 more source

Placebo Effect of Sham Acupuncture for Primary Insomnia: A Meta-Analysis of Randomised Controlled Trials. [PDF]

J Sleep Res
Jiang B, Wang YN, Zhang J, Li HR, Xue PW, Li J, Jin RJ.   +6 more
europepmc   +1 more source

Harnessing the placebo effect to enhance emotion regulation effectiveness and choice. [PDF]

Sci Rep, 2023
Shafir R, Israel M, Colloca L.
europepmc   +1 more source

AMETHYST: A Retrospective Cohort Study of Treatment Patterns and Outcomes in Patients With Glucocorticoid‐Refractory Macrophage Activation Syndrome Complicating Still's Disease

Arthritis &Rheumatology, EarlyView.
Objective Information is limited on the natural history and current treatment patterns in macrophage activation syndrome (MAS), a life‐threatening hyperinflammatory syndrome complicating Still's disease (systemic juvenile idiopathic arthritis [sJIA] and adult‐onset Still's disease [AOSD]).
Alexei Grom, Jordi Antón, Edward M. Behrens, Corey Best, Norbert Blank, Josefin Blomkvist, Scott W. Canna, Sonia Carriquí, Shanmuganathan Chandrakasan, Andrew Danquah, Ngoc‐Bao Duong, Brian D. Jamieson, Paivi Miettunen, Abiola Oladapo, Sampath Prahalad, Pierre Quartier, Grant Schulert, Anna Stoltenberg, Uwe Ullmann, Erika Van Nieuwenhove, Sebastiaan J. Vastert, Fabrizio De Benedetti   +21 more
wiley   +1 more source

The Placebo Effect in Rare Disease Clinical Trials: Measurement, Impact, and Statistical Approaches for Patient-as-Own-Control Designs. [PDF]

Clin Transl Sci
Summar ML, Woodcock J.
europepmc   +1 more source

Cold water immersion after a soccer match: Does the placebo effect occur? [PDF]

Front Physiol, 2023
Nasser N, Zorgati H, Chtourou H, Guimard A.   +3 more
europepmc   +1 more source